Ipamorelin – 10 mg

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone-releasing peptide family. Research has characterized ipamorelin as a selective agonist of the GHS-R1a receptor, providing a research model for investigating growth-hormone secretagogue activity and receptor-mediated signaling. (pubmed.ncbi.nlm.nih.gov) The 10 mg presentation is intended for qualified research environments conducting controlled investigations into GHS-R1a receptor pharmacology, growth-hormone-axis signaling, peptide structure, and related cellular and endocrine pathways.

Key Features

10 mg research-grade Ipamorelin Synthetic pentapeptide Ipamorelin / GHS-R1a research compound Selective growth hormone secretagogue Relevant to growth-hormone receptor and signaling research Suitable for peptide pharmacology studies Intended for controlled in-vitro and preclinical research Appropriate for peptide characterization and analytical workflows Batch-level analytical documentation may be provided for applicable lots Research Focus Ipamorelin was originally characterized for its ability to stimulate growth hormone release through a GHRP-like receptor pathway. Research has investigated its selectivity and receptor pharmacology in laboratory and preclinical models, making it relevant to studies of GHS-R1a signaling and the growth-hormone axis. (pubmed.ncbi.nlm.nih.gov) Ipamorelin remains an investigational research compound rather than an FDA-approved therapeutic product. FDA has also identified potential concerns relating to peptide aggregation, impurities, and limited safety information for compounded ipamorelin acetate. (fda.gov)

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, or prevention of disease. Ipamorelin should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols, analytical requirements, and regulations.